HER2+ Breast Cancer and the risk of recurrence

 

HER2+ breast cancer is typically regarded as an aggressive form of the disease. In this piece, international breast cancer authority Professor Arlene Chan AM discusses the ongoing risk of disease recurrence for HER2+ patients following chemotherapy and trastuzumab-based therapy.